Capricor Therapeutics CFO Acquires Additional Shares

On June 25, 2026, Anthony Bergmann, the Chief Financial Officer of Capricor Therapeutics, Inc. (NasdaqGS: CAPR), purchased 24,100 shares of the company at an average price of $3.18 each. This transaction, which was not part of a pre-planned trading program, had a total value of $76,638.

Insider Buying and Selling at Capricor Therapeutics, Inc.

In addition to Bergmann's purchase, Karen Krasney, Executive Vice President and General Counsel, also bought 24,100 shares at the same price on the same day. Both executives later sold an equal number of shares at a higher price of $30.38 per share, also on June 25.

Other Institutional Activity in Capricor Therapeutics

Several institutional investors have been active in Capricor Therapeutics recently. Suvretta Capital Management, LLC increased its holdings by 2,032,990 shares, bringing its total to 3,818,600 shares valued at approximately $116.1 million, a 113.9% increase. BlackRock, Inc. added 570,837 shares, resulting in a 20% increase to 3,421,815 shares worth about $104 million. Tang Capital Management LLC doubled its position, adding 1,699,900 shares for a total of 3,399,900 shares valued at $103.4 million. State Street Corp grew its stake by 1,352,380 shares to 2,181,901 shares, marking a 163% increase. Vanguard Capital Management LLC opened a new position with 2,027,732 shares, valued at approximately $61.6 million.

Capricor Therapeutics, Inc. Stock Up 148.2%

Shares of Capricor Therapeutics traded near $26.44 on Tuesday. The company has a market capitalization of approximately $1.53 billion. It is currently not profitable, with a forward P/E ratio of -41.17. The stock's 52-week range is between $4.30 and $40.37, with a 50-day moving average of $30.15 and a 200-day moving average of $21.95. The company's beta is relatively low at 0.368, indicating less volatility compared to the broader market.

Analysts Set New Price Targets

On March 13, 2026, B. Riley Securities maintained its buy rating for Capricor Therapeutics, setting a price target of $63. Piper Sandler reiterated its buy rating with a $58 target on the same day. Earlier, on March 10, HC Wainwright & Co. reiterated its buy rating with a $60 target. The consensus among analysts is a strong buy, with an average price target of $53.60 based on 10 analyst opinions.

About Capricor Therapeutics

Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapies for diseases like Duchenne muscular dystrophy (DMD). Headquartered in San Diego, California, and led by CEO Dr. Linda Marbán, the company is advancing its lead product candidate, Deramiocel, through phase 3 clinical trials. Capricor is also working on an exosome-based vaccine for SARS-CoV-2 and other therapeutic candidates. Founded in 2005, the company employs 231 people.

Bottom Line

Anthony Bergmann's recent share purchase adds to the insider activity at Capricor Therapeutics, highlighting confidence in the company's prospects. The stock's recent performance and analyst ratings suggest continued interest in its therapeutic pipeline. Investors should remember that insider transactions are just one piece of the puzzle, and 13F filings offer a backward-looking view of institutional positions.